echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Watson Biotechnology's mRNA COVID-19 vaccine is about to start phase III clinical trials

    Watson Biotechnology's mRNA COVID-19 vaccine is about to start phase III clinical trials

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 11th, the Mexican Foreign Minister announced that the new mRNA vaccine ARCoV developed by a Chinese company will begin phase III clinical trials in Mexico on the 30th of this month, and it is expected that 6,000 volunteers will participate.
    The reporter has confirmed from reliable sources that the mRNA new crown vaccine was jointly developed by the Academy of Military Sciences, Watson Biotechnology and Suzhou Aibo Biotechnology Co.
    , Ltd.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.